Dr Reddy's Laboratories has recalled 58,656 bottles of its heartburn drug Lansoprazole in the United States due to a microbial contamination.
The US Food and Drug Administration has classified the recall of the drug as 'Class II' which indicates a remote chance of severe adverse consequences or death due to the product flaw.
The USFDA has been cracking down heavily on Indian drug makers for non-compliance of manufacturing norms.
The authority imposed a ban on import of drugs from Sun Pharma's Karkhadi facility in Gujarat for violation of manufacturing norms.
Earlier this week, Sun Pharma had voluntarily recalled 2,528 bottles of its generic version of diabetes drug Glumetza in the US market on the basis of a customer complaint.
Among others, some plants of Ranbaxy and Wockhardt have already been banned from importing drugs into the US market.
While all plants of Daiichi Sankyo controlled Ranbaxy Laboratories in India have been banned from exporting drugs to the US, Wockhardt has also faced similar actions on its two plants in the country.
Dr Reddy's Laboratories shares today closed at Rs 2,734.15 on the BSE, up 1.63 per cent from its previous close.
